European UPC Ruling Refuses Block On Soliris Biosimilars

Court Values Alexion’s Disputes With Amgen And Samsung At €100m Apiece

Alexion has been refused in its bid for injunctions to block the sale of Samsung Bioepis and Amgen’s European Soliris biosimilars, following a decision by the Court of Appeal of Europe’s Unified Patent Court.

The UPC’s Court of Appeal refused injunctions (Shutterstock)

Amgen and Samsung Bioepis can continue to sell their Soliris (eculizumab) biosimilars in Europe, after the Court of Appeal of the Unified Patent Court refused originator Alexion’s request for injunctions. Alexion had sought injunctive relief based on its European patent 3,167,888,B1 covering the treatment of paroxysmal nocturnal hemoglobinuria.

Amgen’s Bekemv was the first eculizumab biosimilar to be endorsed in Europe, in early 2023, with Samsung Bioepis

More from Biosimilars

More from Generics Bulletin